Acquista Criptovalute
Paga con
USD
USD
Buy & Sell
Hot
Supports Visa, MasterCard, SEPA & more
P2P
0 Fees
Flexible trading, zero fees
Gate Card
Use your crypto for payments worldwide
Mercati
Trading
Basic
Advanced
Futures
Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Opzioni
Hot
Trade European-style Vanilla Options
Conto unificato
Massimizza l'efficienza del tuo capitale
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Guadagna
Lancia
CandyDrop
Raccogli le caramelle per guadagnare airdrop
Launchpool
Staking rapido, guadagna potenziali nuovi token
HODLer Airdrop
Fai holding GT e ottieni enormi airdrop gratuitamente
Pre-IPOs
tag
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Investimento
Square
Square
Post, share, and explore crypto trends
Live
moments live
Live crypto market analysis
Chat
Chat with crypto traders
News
What is happening in crypto
flower_head
Altro
Promozioni
AI
Altro
TradFi
WCTC S8
Rewards
CLS

Prezzo Celestica Inc

CLS
$379,07
-$5,28(-1,37%)

*Data last updated: 2026-04-15 16:36 (UTC+8)

As of 2026-04-15 16:36, Celestica Inc (CLS) is priced at $379,07, with a total market cap of $44,18B, a P/E ratio of 40,23, and a dividend yield of 0,00%. Today, the stock price fluctuated between $378,80 and $393,00. The current price is 0,07% above the day's low and 3,54% below the day's high, with a trading volume of 3,49M. Over the past 52 weeks, CLS has traded between $271,95 to $393,00, and the current price is -3,54% away from the 52-week high.

CLS Key Stats

Yesterday's Close$365,46
Market Cap$44,18B
Volume3,49M
P/E Ratio40,23
Dividend Yield (TTM)0,00%
Diluted EPS (TTM)7,24
Net Income (FY)$847,07M
Revenue (FY)$12,60B
Earnings Date2026-04-27
EPS Estimate2,07
Revenue Estimate$3,94B
Shares Outstanding120,91M
Beta (1Y)1.354

About CLS

Celestica Inc. provides hardware platform and supply chain solutions in North America, Europe, and Asia. It operates through two segments, Advanced Technology Solutions, and Connectivity & Cloud Solutions. The company offers a range of product manufacturing and related supply chain services, including design and development, engineering, supply chain management, new product introduction, component sourcing, electronics manufacturing and assembly, testing, complex mechanical assembly, systems integration, precision machining, order fulfillment, logistics, asset management, product licensing, and after-market repair and return services. It also provides enterprise-level data communications and information processing infrastructure products, such as routers, switches, data center interconnects, edge solutions, servers, and storage-related products; capacitors, microprocessors, resistors, and memory modules; and power inverters, energy storage products, smart meters, and other electronic componentry products. The company serves aerospace and defense, industrial, energy, healthtech, capital equipment, original equipment manufacturers, cloud-based, and other service providers, including hyperscalers, and other companies in a range of industries. Celestica Inc. was incorporated in 1994 and is headquartered in Toronto, Canada.
SectorTechnology
IndustryHardware, Equipment & Parts
CEORobert Andrew Mionis
HeadquartersToronto,ON,CA
Official Websitehttps://www.celestica.com

Celestica Inc (CLS) FAQ

What's the stock price of Celestica Inc (CLS) today?

x
Celestica Inc (CLS) is currently trading at $379,07, with a 24h change of -1,37%. The 52-week trading range is $271,95–$393,00.

What are the 52-week high and low prices for Celestica Inc (CLS)?

x

What is the price-to-earnings (P/E) ratio of Celestica Inc (CLS)? What does it indicate?

x

What is the market cap of Celestica Inc (CLS)?

x

What is the most recent quarterly earnings per share (EPS) for Celestica Inc (CLS)?

x

Should you buy or sell Celestica Inc (CLS) now?

x

What factors can affect the stock price of Celestica Inc (CLS)?

x

How to buy Celestica Inc (CLS) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

CLS
CFD
Fai trading

Celestica Inc (CLS) Latest News

2026-04-13 13:31

TradFi Rise Alert: CLS (Celestica Inc) Rises Over 6%

Gate News: According to the latest Gate TradFi data, CLS (Celestica Inc) has surged by 6% in a short period. Current volatility is significantly higher than recent averages, indicating increased market activity.

2026-02-05 00:41

美 SEC 对 ZM Quant、Gotbit 和 CLS Global 三家加密做市商提起市场操纵指控

ChainCatcher 消息，据 Financefeeds 报道，美国证券交易委员会（SEC）已对三家加密做市商——ZM Quant、Gotbit 和 CLS Global 提起市场操纵指控。SEC 指控这三家公司利用算法进行虚假交易，制造人为交易量，欺骗散户投资者。同时，SEC 还起诉了九名个人，包括推广者和公司员工，指控他们雇用操纵服务并执行无意义交易，违反了证券法中的反欺诈和注册条款。 作为调查的一部分，美国联邦调查局（FBI）通过一个名为 NexFundAI 的虚构代币进行了诱捕行动，揭露了这些公司参与虚假交易的意愿。此案已导致15个实体被起诉，并引发了相关刑事诉讼。

2025-12-06 00:56

SpaceX拟以8000亿美元估值出售内部股份，计划明年下半年上市

PANews 12月6日消息，据财联社报道，知情人士透露，SpaceX 正就出售内部股份进行谈判，此笔交易将使埃隆·马斯克旗下的火箭和卫星制造商估值达到 8000 亿美元。若消息得到证实，这起新交易将使 SpaceX 再次成为全球估值最高的初创企业，超越此前由 OpenAI 在 10 月创下的 5000 亿美元估值纪录。这一估值相较于7月份设定的每股 212 美元有大幅增长，当时该公司以 4000 亿美元的估值筹集资金并出售股份。 两位熟悉相关讨论的人士透露，SpaceX 已告知投资者及金融机构代表，公司计划于明年下半年进行首次公开募股（IPO）。此次洽谈正值 SpaceX 考虑对投资者持有的股份进行出售之际。

2025-10-14 07:14

SMART（SMART）24小时上涨7.75%

Gate News Bot 消息，10月14日，据CoinMarketCap行情，截至发稿时，SMART（SMART）现报 0.00 美元，24 小时内上涨7.75%，最高触及 0.00 美元，最低回落至 0.00 美元。当前市值约为 2710 万美元，较昨日增长 195 万美元。 SMART Blockchain 是一个旨在解决加密市场问题的项目，提供最稳定的去中心化网络运行，并简化可扩展性。其主要特点包括随时随地的即时交易、无中间商、24/7 运营、安全性、独立性、匿名性以及自由兑换其他加密货币。SMART 协议使所有爱好者能够在其网络上快速轻松地构建项目。该项目起源于 2016 年的瑞士，由一个在加密产品和支付系统方面经验丰富的专业开发团队创立。目前，全球数百人正在开发该集团的项目，其社区拥有超过 200 万用户。 SMART近期重要消息： 1️⃣ **智能合约钱包技术发展** 智能合约钱包正在成为加密货币领域的一个重要发展方向。这种新型钱包通过智能合约技术提供更高的安全性和灵活性，有望推动SMART等智能合约平台的应用范围进一步扩大。 2️⃣ **CLS集团推出智能合约服务** 金融服务提供商CLS集团近期推出了基于智能合约的新服务。这一举措表明传统金融机构对智能合约技术的认可度不断提升，可能为SMART等专注于智能合约的项目带来新的发展机遇。 3️⃣ **SMART价值评估工具更新** 多个加密货币数据平台更新了SMART代币的价值评估工具，为投资者提供了更准确的市场信息。这有助于提高SMART的市场透明度，可能是近期价格上涨的一个推动因素。 从技术面来看，SMART的24小时涨幅达7.75%，显示出较强的上涨动能。然而，考虑到加密货币市场的高波动性，投资者仍需谨慎关注市场风险。 此消息不作为投资建议，投资需注意市场波动风险。

2025-04-17 14:21

SEC处罚阿联酋加密资产做市商CLS Global操纵市场案

Gate.io News bot消息，据吴说报道，美国马萨诸塞州地方法院于4月7日对阿联酋实体做市商CLS Global FZC LLC作出最终判决。美国证券交易委员会（SEC）此前指控该自称加密资产做市商的公司通过操控"NexFundAI"市场诱导投资者购买，制造虚假活跃交易假象。SEC认定"NexFundAI"为证券。 CLS Global接受法院判决，将支付42.5万美元民事罚款及3000美元非法所得追缴。该公司需立即停止与美国用户或实体进行业务往来，并在未来三年内每年提交合规证明。

Hot Posts su Celestica Inc (CLS)

SelfRugger

SelfRugger

04-13 22:09
This is a paid press release. Contact the press release distributor directly with any inquiries. FDA Approves FILKRI™ (filgrastim-laha), Accord BioPharma's Biosimilar to NEUPOGEN® (filgrastim) =============================================================================================== PR Newswire Tue, February 17, 2026 at 10:05 PM GMT+9 11 min read _FILKRI completes Accord BioPharma's comprehensive_ _granulocyte colony-stimulating factor (G-CSF) portfolio alongside UDENYCA® (pegfilgrastim-cbqv_) RALEIGH, N.C., Feb. 17, 2026 /PRNewswire/ -- Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and critical care therapies, announced that the U.S. Food and Drug Administration (FDA) has approved FILKRI™ (filgrastim-laha), a biosimilar to NEUPOGEN® (filgrastim), for patients with cancer receiving myelosuppressive chemotherapy; patients with acute myeloid leukemia receiving induction or consolidation chemotherapy; patients with cancer undergoing bone marrow transplantation; patients with severe chronic neutropenia; and patients acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome).1 Accord BioPharma Logo (PRNewsfoto/Accord BioPharma) The approval of FILKRI marks the sixth product in Accord BioPharma's growing portfolio of FDA-approved biosimilars, following the company's acquisition last year of UDENYCA® (pegfilgrastim-cbqv), a biosimilar to Neulasta® (pegfilgrastim),2 as well as the seventh approved product in the overall portfolio. With the addition of FILKRI, Accord BioPharma now offers physicians in the U.S. a comprehensive granulocyte colony-stimulating factor (G-CSF) portfolio with both long-acting (UDENYCA) and short-acting (FILKRI) biosimilar options to meet the needs of patients, providers, and practices.1,2 Accord has applied for and expects to receive a permanent Q-code from the U.S. Centers for Medicare & Medicaid Services (CMS), which will standardize and facilitate the billing and reimbursement process across hospital outpatient, ambulatory surgery center, and physician office settings of care. **Tackling Vital Healthcare Needs  **Neutropenia is a common and potentially serious complication of cancer treatment and occurs when white blood cells called neutrophils—which serve as a major line of defense against bacterial and fungal infections—fall below normal levels. This reduction increases a person's risk of developing an infection. Granulocyte colony-stimulating factor, or G-CSF, is a growth factor that stimulates the production and release of neutrophils in the body. By accelerating neutrophil recovery, G-CSF can help reduce the duration of neutropenia.3,4 FILKRI belongs to the G-CSF class and is a growth factor manufactured by recombinant DNA technology. FILKRI works by regulating the production of neutrophils within the bone marrow.1 "Cancer patients often face significant challenges with treatment-related neutropenia, which can lead to serious infections, treatment delays, and dose reductions that may compromise therapeutic outcomes," said Chrys Kokino, President, Accord North America. "With FILKRI alongside UDENYCA, the provider-preferred option over Neulasta and all other biosimilars,* we now offer healthcare providers a complete G-CSF portfolio with short- and long-acting biosimilar options. This positions Accord BioPharma as a committed partner in oncology supportive care, expanding access to high-quality biologics." Story continues **Demonstrated Biosimilarity and Safety Profile **FILKRI was approved based on two randomized studies in healthy adults, with pharmacokinetics (PK)/pharmacodynamics (PD) assessed in one study and safety and immunogenicity evaluated in both, compared with reference product NEUPOGEN. These studies demonstrated the biosimilarity in PD and PK parameters between FILKRI and NEUPOGEN and showed overall safety and immunogenicity similar to NEUPOGEN.5 FILKRI is contraindicated in patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors, such as filgrastim products or pegfilgrastim products.1 **Expanding Access: Accord BioPharma's Biosimilar Vision **Accord BioPharma believes deeply in the power of biosimilars to reshape the future of treatment. With the support of Intas, an established global leader with nearly five decades of experience, Accord BioPharma is transforming the conventional treatment landscape across several priority therapeutic areas by introducing biosimilars to the U.S. market. As part of this commitment, Accord BioPharma is rapidly expanding its U.S. portfolio with a strategic goal to launch 20 biosimilar products by 2030, solidifying its position as a reliable partner delivering more affordable, high-quality biologic alternatives. In addition to developing and marketing their own biosimilar products, the company is strategically collaborating with select partners around the world to bring more biosimilars to the U.S. market as swiftly as possible. "This approval of FILKRI demonstrates our steadfast dedication to expanding access to cost-effective biologic treatments in the critically important field of oncology," said Binish Chudgar, Chairman and Managing Director of Intas Pharmaceuticals. "We're proud to have one of the largest biosimilar pipelines within the industry. With Accord BioPharma, we're positioning ourselves as a dependable partner in the United States—one that's deeply committed to understanding stakeholder priorities and revolutionizing patient access." **Current Portfolio of Brands **The company's current commercial portfolio includes the full UDENYCA franchise, including the UDENYCA prefilled syringe, autoinjector, and on-body injector, IMULDOSA® (ustekinumab-srlf), a biosimilar to Stelara® (ustekinumab), HERCESSI™ (trastuzumab-strf), a biosimilar to Herceptin® (trastuzumab), and CAMCEVI® (leuprolide) 42 mg injectable emulsion.6,7 Please refer to the Important Safety Information and full Prescribing Information for these products, and to the Boxed Warning for HERCESSI. Accord BioPharma has received FDA approval on three additional products: CAMCEVI® (leuprolide) ETM (every three months), OSVYRTI® (denosumab-desu), a biosimilar to PROLIA® (denosumab), and JUBEREQ® (denosumab-desu), a biosimilar to XGEVA® (denosumab).8,9 The company plans to announce the commercial launch of these products later this year. Please refer to the Important Safety Information and full Prescribing Information for these products, and to the Boxed Warning for OSVYRTI. **Contact:  ****abipr@accordhealthcare.com** **IMPORTANT SAFETY INFORMATION ** **FILKRI is contraindicated **in patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors (G-CSFs) such as filgrastim or pegfilgrastim products. **Splenic Rupture: **Splenic rupture, including fatal cases, has been reported following the administration of filgrastim products. Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture. **Acute Respiratory Distress Syndrome (ARDS): **ARDS has been reported in patients receiving filgrastim products**. **Evaluate patients who develop fever and lung infiltrates or respiratory distress for ARDS**. **Discontinue FILKRI in patients with ARDS. **Serious Allergic Reactions: **Serious allergic reactions, including anaphylaxis, have been reported in patients receiving filgrastim products**. **The majority of reported events occurred upon initial exposure**. **Provide symptomatic treatment for allergic reactions. Allergic reactions, including anaphylaxis, in patients receiving filgrastim products can recur within days after the discontinuation of initial anti-allergic treatment**. **Permanently discontinue FILKRI in patients with serious allergic reactions. **Sickle Cell Disorders: **Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving filgrastim products**. **Discontinue FILKRI if sickle cell crisis occurs. **Glomerulonephritis: **Has occurred in patients receiving filgrastim products**. **Diagnoses were based on azotemia, hematuria, proteinuria, and renal biopsy**. **Generally, events resolved after dose reduction or discontinuation of filgrastim products**. **If causality is likely, consider dose-reduction or interruption of FILKRI. **Alveolar Hemorrhage and Hemoptysis: **Alveolar hemorrhage, manifesting as pulmonary infiltrates and hemoptysis requiring hospitalization, have been reported in FILKRI-treated healthy donors undergoing peripheral blood progenitor cell (PBPC) collection mobilization**. **Hemoptysis resolved with discontinuation of filgrastim products. The use of FILKRI for PBPC mobilization in healthy donors is not an approved indication. **Capillary Leak Syndrome (CLS): **CLS has been reported after G-CSF administration, including filgrastim products and is characterized by hypotension, hypoalbuminemia, edema, and hemoconcentration. Episodes vary in frequency, severity, and may be life-threatening if treatment is delayed**. **Patients with symptoms should be closely monitored and receive appropriate treatment. **Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML): ** **Patients with Severe Chronic Neutropenia (SCN****): **Confirm the diagnosis of SCN before initiating FILKRI therapy. MDS and AML have been reported to occur in the natural history of congenital neutropenia without cytokine therapy. Cytogenetic abnormalities, transformation to MDS, and AML have also been observed in patients treated with filgrastim products for SCN. Abnormal cytogenetics and MDS have been associated with the eventual development of myeloid leukemia. The effect of filgrastim products on the development of abnormal cytogenetics and the effect of continued filgrastim administration in patients with abnormal cytogenetics or MDS are unknown. Monitor patients for signs and symptoms of MDS/AML in these settings. If a patient with SCN develops abnormal cytogenetics or myelodysplasia‚ the risks and benefits of continuing FILKRI should be carefully considered. **Patients with Breast and Lung Cancer****: **MDS and AML have been associated with the use of filgrastim products in conjunction with chemotherapy and/or radiotherapy in patients with breast and lung cancer. Monitor patients for signs and symptoms of MDS/AML in these settings. **Thrombocytopenia: **Thrombocytopenia has been reported in patients receiving filgrastim products. Monitor platelet counts. **Leukocytosis: ** **Patients with Cancer Receiving Myelosuppressive Chemotherapy****: **White blood cell counts ≥ 100,000/mm2 were observed in about 2% of patients who received filgrastim products at dosages above 5 mcg/kg/day. Discontinue FILKRI if the absolute neutrophil count (ANC) surpasses 10,000/mm2 after the chemotherapy-induced ANC nadir has occurred. Monitor CBCs at least twice weekly during therapy with FILKRI. Discontinuation of filgrastim therapy usually resulted in a 50% decrease in circulating neutrophils within 1 to 2 days‚ with a return to pretreatment levels in 1 to 7 days. **Cutaneous Vasculitis: **Moderate or severe cases of cutaneous vasculitis has been reported in patients treated with filgrastim products**. **Most reports involved patients with SCN receiving long-term filgrastim therapy**. **Hold FILKRI therapy in patients with cutaneous vasculitis**. **FILKRI dose may be reduced when the symptoms resolve and the ANC has decreased. **Potential Effect on Malignant Cells: **FILKRI is a growth factor that primarily stimulates neutrophils. The granulocyte colony-stimulating factor (G-CSF) receptor through which FILKRI acts has also been found on tumor cell lines. The possibility that FILKRI acts as a growth factor for any tumor type cannot be excluded. The safety of filgrastim products in chronic myeloid leukemia (CML) and myelodysplasia has not been established. **Simultaneous Use with Chemotherapy and Radiation Not Recommended: **The safety and efficacy of FILKRI given simultaneously with cytotoxic chemotherapy and radiation have not been established**. **Do not use FILKRI 24 hours before or after administration of cytotoxic chemotherapy**. **The safety and efficacy of FILKRI have not been evaluated in patients receiving concurrent radiation therapy**. **Avoid the simultaneous use of FILKRI with chemotherapy and radiation therapy. **Nuclear Imaging: **Increased hematopoietic activity of the bone marrow has been associated with transient positive bone-imaging changes on nuclear imaging. **Aortitis: **Aortitis has been reported in patients receiving filgrastim products**. **It may occur as early as the first week after start of therapy**. **Manifestations may include generalized signs and symptoms such as fever, abdominal pain, malaise, back pain, and increased inflammatory markers (e.g., c-reactive protein and white blood cell count)**. **Consider aortitis in patients who develop these signs and symptoms without known etiology. Discontinue FILKRI if aortitis is suspected. **The most common adverse reactions in patients: ** * **with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs **(≥ 5% difference in incidence compared to placebo) are pyrexia, pain, rash, cough, and dyspnea * **with AML **(≥ 2% difference in incidence) are pain, epistaxis and rash * **with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by BMT **(≥ 5% difference in incidence) is rash * **with severe chronic neutropenia (SCN) **(≥ 5% difference in incidence) are pain, anemia, epistaxis, diarrhea, hypoesthesia and alopecia **INDICATIONS ** FILKRI is a leukocyte growth factor indicated to: * Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever * Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) * Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT) * Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia * Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome) **To report SUSPECTED ADVERSE REACTIONS, contact Accord BioPharma Inc at 1-866-941-7875 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. ** FILKRI is supplied as single-dose prefilled syringes for subcutaneous or intravenous use in 300 mcg/0.5 mL and 480 mcg/0.8 mL strengths. **For more information, please see the full Prescribing Information. ** **About Accord BioPharma **Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., seeks to provide affordable, accessible, patient-centric therapies in oncology, immunology, and critical care. With a focus on improving the patient experience, Accord BioPharma goes beyond the biology of medicine to see disease from the patients' perspective and develop high-quality therapies that impact patients' lives. Accord BioPharma believes in the ability of biosimilars to increase access and options for patients and deliver savings to the U.S. healthcare system, and is striving to offer one of the deepest biosimilar portfolios in the industry. For more information, visit **AccordBioPharma.com**. *Based on cumulative average of prescriptions written from September 2025 - January 2026, according to IQVIA drug distribution data. **References: ** 1. FILKRI® (filgrastim-laha) injection. Prescribing Information. Accord BioPharma. 2. UDENYCA® (pegfilgrastim-cbqv). Prescribing Information. Accord BioPharma. 3. Simpson, P. Clinical Implications and Future Research of Neutrophils in Health and Disease. _Immunome Research_ 2024;20(3): 1-2. 4. Link, H. Current state and future opportunities in granulocyte colony‑stimulating factor (G‑CSF). _Supportive Care in Cancer_ 2022;30:7067–7077. 5. Accord BioPharma. Data on file. 6. IMULDOSA® (ustekinumab-srlf). Prescribing Information. Accord BioPharma. 7. HERCESSI™ (trastuzumab-strf). Prescribing Information. Accord BioPharma. 8. OSVYRTI® (denosumab-desu). Prescribing Information. Accord BioPharma. 9. JUBEREQ® (denosumab-desu). Prescribing Information. Accord BioPharma. All trademarks, logos, and brand names are the property of their respective owners. Cision View original content to download multimedia: Terms and Privacy Policy Privacy Dashboard More Info
0
0
0
0
MarketMaestro

MarketMaestro

04-13 15:13
$CLS With the BoS breakout, the move could accelerate again
BOS+1,87%
0
0
0
0
GateNews

GateNews

04-13 13:31
Gate News: According to the latest Gate TradFi data, CLS (Celestica Inc) has surged by 6% in a short period. Current volatility is significantly higher than recent averages, indicating increased market activity.
0
0
0
0